Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. Jarskog LF, et al. Among authors: maruff p. Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24. Schizophr Res. 2015. PMID: 25728831 Clinical Trial.
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation.
Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. Nathan PJ, et al. Among authors: maruff p. Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003. Curr Alzheimer Res. 2013. PMID: 23521503 Clinical Trial.
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP. Grove RA, et al. Among authors: maruff p. Curr Alzheimer Res. 2014 Jan;11(1):47-58. doi: 10.2174/1567205010666131212110148. Curr Alzheimer Res. 2014. PMID: 24359500 Clinical Trial.
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T. Desai A, et al. Among authors: maruff p. Neuropsychopharmacology. 2021 May;46(6):1145-1151. doi: 10.1038/s41386-020-00908-0. Epub 2020 Nov 17. Neuropsychopharmacology. 2021. PMID: 33203954 Free PMC article. Clinical Trial.
Behavioral characterization of mild cognitive impairment.
Collie A, Maruff P, Currie J. Collie A, et al. Among authors: maruff p. J Clin Exp Neuropsychol. 2002 Sep;24(6):720-33. doi: 10.1076/jcen.24.6.720.8397. J Clin Exp Neuropsychol. 2002. PMID: 12424647
532 results